The Zhitong Finance App learned that BOC International released a research report saying that Moderna and MSD's personalized mRNA tumor vaccine IntiSmeran achieved positive results in the melanoma phase III study, providing clinical verification for this new treatment paradigm, and also highlights the forward-looking layout of Genting Xinyao (01952.HK) in this field; the bank maintains a “buy” rating and is optimistic about the company's efficient BD+ commercialization execution and the continued progress of mRNA cancer vaccines/in vivo CAR-T.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.